Skip to main content
Erschienen in: Advances in Therapy 4/2019

08.03.2019 | Original Research

Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study

verfasst von: Qian Cai, Charmi Patel, Edward Kim, Nancy Connolly, Ozgur Tunceli, Antoine C. El Khoury

Erschienen in: Advances in Therapy | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Factors underlying the selection of antipsychotics for patients with schizophrenia are poorly understood. This study investigated variables associated with initiation of treatment with the long-acting injectables paliperidone palmitate (LAI-PP) and aripiprazole LAI (LAI-AP) in Medicaid patients with schizophrenia.

Methods

Adults with at least one medical or pharmacy claim for LAI-PP or LAI-AP from 1 January 2013 to 31 December 2016 were selected from the IBM® MarketScan® Medicaid Database. The date of the first LAI-PP or LAI-AP claim was the index date. Patients who had at least two medical claims, on different days, for a schizophrenia diagnosis and at least 12 months of continuous health plan enrollment prior to index date were included in the analysis. Multivariable logistic regression was performed to determine the factors associated with the initiation of LAI-PP versus LAI-AP.

Results

Of included patients, 5501 initiated LAI-PP and 1449 initiated LAI-AP. Patients more likely to initiate LAI-PP versus LAI-AP were older, male, or African American (all p < 0.01). Patients with obesity (odds ratio [OR] 0.84; 95% confidence interval [CI] 0.71, 0.98), post-traumatic stress disorder (OR 0.76; 95% CI 0.63, 0.92), or prior oral antipsychotic use (OR 0.66; 95% CI 0.55, 0.79) were less likely to initiate LAI-PP; whereas, patients with nonorganic psychoses (OR 1.35; 95% CI 1.18, 1.55) or prior use of other injectable antipsychotics (OR 1.26; 95% CI 1.09, 1.47) were more likely to initiate LAI-PP versus LAI-AP. Patients with at least two all-cause hospitalizations were 1.37 times more likely to initiate LAI-PP vs LAI-AP (OR 1.37; 95% CI 1.18, 1.60).

Conclusion

Factors associated with initiating LAI-PP and LAI-AP differed. Notably, patients who initiated LAI-PP had greater prior use of medical services than LAI-AP patients. Understanding prescribing practices may help optimize treatment strategies and improve disease management.

Funding

Janssen Scientific Affairs, LLC.
Literatur
4.
Zurück zum Zitat Fitch K, Iwasaki K, Villa KF. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benef. 2014;7(1):18–26. Fitch K, Iwasaki K, Villa KF. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benef. 2014;7(1):18–26.
7.
Zurück zum Zitat Jakovljevic M. Long-acting injectable (depot) antipsychotics and changing treatment philosophy: possible contribution to integrative care and personal recovery of schizophrenia. Psychiatr Danub. 2014;26(4):304–7.PubMed Jakovljevic M. Long-acting injectable (depot) antipsychotics and changing treatment philosophy: possible contribution to integrative care and personal recovery of schizophrenia. Psychiatr Danub. 2014;26(4):304–7.PubMed
9.
11.
14.
Zurück zum Zitat Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013;13:221. https://doi.org/10.1186/1471-244X-13-221. Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013;13:221. https://​doi.​org/​10.​1186/​1471-244X-13-221.
17.
Zurück zum Zitat Cuomo I, Kotzalidis GD, de Persis S, et al. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat. 2018;14:1645–56. https://doi.org/10.2147/NDT.S171002. Cuomo I, Kotzalidis GD, de Persis S, et al. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat. 2018;14:1645–56. https://​doi.​org/​10.​2147/​NDT.​S171002.
21.
22.
Zurück zum Zitat Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs. 1996;6(5):367–81.CrossRef Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs. 1996;6(5):367–81.CrossRef
23.
Zurück zum Zitat Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56 Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56
24.
Zurück zum Zitat Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44. https://doi.org/10.3109/15622975.2012.739708. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44. https://​doi.​org/​10.​3109/​15622975.​2012.​739708.
26.
Zurück zum Zitat Sajatovic M, Ross R, Legacy SN, et al. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018;14:1475–92. https://doi.org/10.2147/NDT.S167485. Sajatovic M, Ross R, Legacy SN, et al. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018;14:1475–92. https://​doi.​org/​10.​2147/​NDT.​S167485.
27.
Zurück zum Zitat Department of Health and Human Services National Institutes of Health Office for Protection from Research Risks. Code of Federal Regulations, Title 45, public welfare, part 46, protection of human subjects §46.101 2006. 1991. https://www.unmc.edu/irb/_documents/45cfr46.pdf (revised June 18, 1991; accessed 14 Feb 2019). Department of Health and Human Services National Institutes of Health Office for Protection from Research Risks. Code of Federal Regulations, Title 45, public welfare, part 46, protection of human subjects §46.101 2006. 1991. https://​www.​unmc.​edu/​irb/​_​documents/​45cfr46.​pdf (revised June 18, 1991; accessed 14 Feb 2019).
32.
Zurück zum Zitat Rajagopalan K, Hassan M, Boswell K, Sarnes E, Meyer K, Grossman F. Review of outcomes associated with restricted access to atypical antipsychotics. Am J Manag Care. 2016;22(6):e208–e214214.PubMed Rajagopalan K, Hassan M, Boswell K, Sarnes E, Meyer K, Grossman F. Review of outcomes associated with restricted access to atypical antipsychotics. Am J Manag Care. 2016;22(6):e208–e214214.PubMed
35.
36.
Zurück zum Zitat Joshi K, Lafeuille MH, Kamstra R, et al. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits. J Comp Eff Res. 2018;7(2):121–33. https://doi.org/10.2217/cer-2017-0043.CrossRefPubMed Joshi K, Lafeuille MH, Kamstra R, et al. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits. J Comp Eff Res. 2018;7(2):121–33. https://​doi.​org/​10.​2217/​cer-2017-0043.CrossRefPubMed
37.
Zurück zum Zitat Gaviria AM, Franco J, Rico G, et al. Noninterventional, naturalistic, retrospective study to describe prescription patterns of long-acting injectable antipsychotics and the impact of introducing a new atypical antipsychotic in the Spanish province of Tarragona catchment area. Prim Care Companion CNS Disord. 2017. https://doi.org/10.4088/PCC.16m02044. Gaviria AM, Franco J, Rico G, et al. Noninterventional, naturalistic, retrospective study to describe prescription patterns of long-acting injectable antipsychotics and the impact of introducing a new atypical antipsychotic in the Spanish province of Tarragona catchment area. Prim Care Companion CNS Disord. 2017. https://​doi.​org/​10.​4088/​PCC.​16m02044.​
42.
Zurück zum Zitat Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull. 2003;29(2):183–93.CrossRefPubMed Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull. 2003;29(2):183–93.CrossRefPubMed
43.
Zurück zum Zitat Kohen I, Lester PE, Lam S. Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole. Neuropsychiatr Dis Treat. 2010;6:47–58.CrossRefPubMedPubMedCentral Kohen I, Lester PE, Lam S. Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole. Neuropsychiatr Dis Treat. 2010;6:47–58.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Kari F, Bryan B, Paul J. The use of claims data in healthcare research. Open Public Health J. 2009;2(1) Kari F, Bryan B, Paul J. The use of claims data in healthcare research. Open Public Health J. 2009;2(1)
45.
Zurück zum Zitat Walsh EG, Clark WD. Managed care and dually eligible beneficiaries: challenges in coordination. Health Care Financ Rev. 2002;24(1):63–82.PubMedPubMedCentral Walsh EG, Clark WD. Managed care and dually eligible beneficiaries: challenges in coordination. Health Care Financ Rev. 2002;24(1):63–82.PubMedPubMedCentral
Metadaten
Titel
Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study
verfasst von
Qian Cai
Charmi Patel
Edward Kim
Nancy Connolly
Ozgur Tunceli
Antoine C. El Khoury
Publikationsdatum
08.03.2019
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 4/2019
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-00913-w

Weitere Artikel der Ausgabe 4/2019

Advances in Therapy 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.